HC Wainwright Predicts Xeris Biopharma FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Xeris Biopharma to $0.14 from $0.04, while keeping its Buy rating and $18 price target. It also forecasts $0.13 EPS in FY2027 and $1.03 in FY2030.
• Xeris reported quarterly EPS of $0.06, beating the $0.03 consensus, and revenue of $107.23 million, above the $101.68 million estimate.
• Analyst views are mixed but lean positive: MarketBeat’s consensus rating is Moderate Buy with a $16.20 average price target; Piper Sandler maintained Neutral, while Oppenheimer raised its target to $21 and reiterated Outperform.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Research analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Friday, November 6th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.14 per share for the year, up from their prior estimate of $0.04. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Xeris Biopharma's current full-year earnings is $0.07 per share. HC Wainwright also issued estimates for Xeris Biopharma's Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $0.13 EPS and FY2030 earnings at $1.03 EPS.

Several other research firms have also weighed in on XERS. Piper Sandler restated a "neutral" rating and set a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Wall Street Zen raised shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xeris Biopharma in a research note on Wednesday, November 4th. Oppenheimer reiterated an "outperform" rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a research note on Friday. Finally, Barclays increased their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an "overweight" rating in a research report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $16.20.

Xeris Biopharma Trading Up 4.3%

NASDAQ XERS opened at $15.86 on Tuesday. The business's fifty day moving average is $9.77 and its 200-day moving average is $7.66. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -317.14 and a beta of 0.61. Xeris Biopharma has a one year low of $5.25 and a one year high of $15.94.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The firm had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 25,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the sale, the insider directly owned 1,086,130 shares in the company, valued at $11,111,109.90. This represents a 2.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the business's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $12.49, for a total transaction of $312,250.00. Following the completion of the transaction, the insider owned 1,559,208 shares in the company, valued at $19,474,507.92. The trade was a 1.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds have recently made changes to their positions in the company. Royce & Associates LP raised its holdings in Xeris Biopharma by 27.5% in the third quarter. Royce & Associates LP now owns 588,178 shares of the company's stock worth $5,623,000 after purchasing an additional 127,025 shares in the last quarter. Knights of Columbus Asset Advisors LLC purchased a new position in Xeris Biopharma during the third quarter valued at $1,275,000. StoneX Group Inc. purchased a new position in Xeris Biopharma during the third quarter valued at $142,000. Pictet Asset Management Holding SA lifted its position in Xeris Biopharma by 13.7% during the third quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company's stock valued at $326,000 after buying an additional 4,108 shares during the period. Finally, AlphaCentric Advisors LLC boosted its holdings in shares of Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company's stock valued at $464,000 after buying an additional 1,940 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Key Stories Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for FY2026 to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The firm reiterated its Buy rating and $18 price target. Xeris analyst estimates
• Positive Sentiment: Wall Street Zen upgraded Xeris, while Oppenheimer reiterated its Outperform rating; another report says the consensus brokerage view is Moderate Buy. Wall Street Zen upgrade Brokerage consensus Oppenheimer rating
• Neutral Sentiment: Piper Sandler reiterated a Neutral rating, tempering the otherwise positive analyst commentary. Piper Sandler rating

Xeris Biopharma Company Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative.

The company also develops drug-delivery technologies intended to make medicines easier to store and administer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.